每周特立帕肽对比双膦酸盐对骨质疏松患者多节段腰椎融合术后6个月骨融合的影响:多中心前瞻性随机研究
多中心前瞻性随机研究纳入骨质疏松患者,比较每周特立帕肽与双膦酸盐在多节段腰椎椎间融合术后6个月的骨融合情况,发现两组骨融合评分无显著差异,但术后即刻植骨骨接触状态对6个月融合率有显著影响。
要点
- 每周特立帕肽与双膦酸盐组6个月骨融合评分无显著差异。
- 术后即刻CT显示骨接触阳性患者6个月融合率显著高于阴性患者。
- 多节段腰椎融合术后骨接触状态是融合的重要影响因素。
核心结论
- 在多节段腰椎椎间融合术中,每周特立帕肽与双膦酸盐治疗患者的骨融合评分无显著差异。
研究设计与样本
- 多中心前瞻性随机研究,纳入年龄大于50岁的骨质疏松患者,随机分为每周特立帕肽组(N=50)和双膦酸盐组(N=54)。
主要发现
- 术后6个月平均骨融合评分:特立帕肽组3.9分,双膦酸盐组4.2分。
- 术后6个月骨融合率:特立帕肽组46.8%,双膦酸盐组32.7%,特立帕肽组有更高趋势。
- 术后即刻骨接触阳性患者6个月融合率显著高于骨接触阴性患者(47.4% vs. 9.5%)。
关键数值与推荐
- 骨融合评分范围为2至6分,2分定义为完全融合。
- 骨融合评估在固定范围最底部的椎间盘进行。
临床怎么用
- 对于多节段腰椎椎间融合的骨质疏松患者,术后即刻植骨骨接触状态对6个月融合率有重要影响,应关注术中植骨接触情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: Multicenter, prospective randomized study. OBJECTIVE: Evaluate the impact of weekly teriparatide (WT) and bone contact (BC) status of grafted bone in patients recovering from multilevel lumbar interbody fusion (M-LIF). SUMMARY OF BACKGROUND DATA: WT has been reported to significantly improve bone fusion following posterior or transforaminal interbody fusion in osteoporosis patients. METHODS: Patients older than 50 years and osteoporotic were recruited. We defined the fusion of two or more consecutive intervertebral levels as M-LIF. All patients were instrumented with pedicle, iliac, or S-2 alar iliac screws after transplanting cages and autogenous bone between vertebral bodies. After surgical indication for M-LIF, the subjects were randomly allocated to receive either subcutaneous WT from 1 week to 6 months postoperatively (WT arm, N = 50) or a bisphosphonate (BP; BP arm, N = 54). Blinded radiological evaluations were performed using computed tomography (CT). Evaluation of bone fusion was performed at the intervertebral disc located at the bottom of the fixed range. The degree of bone fusion was calculated as a score from 2 to 6 points, with 2 defined as complete fusion. Bone fusion rate was also compared at 6 months postoperatively based on BC status of the grafted bone on CT immediately after surgery. RESULTS: Mean bone fusion score at 6 months postoperatively was 3.9 points in the WT group and 4.2 points in the BP group. The bone fusion rate at 6 months postoperatively tended to be higher in the WT group (46.8% vs. 32.7% in the BP group). The 6-month postoperative fusion rate of immediately postoperative of BC+ patients was significantly higher than that of BC- patients (47.4% vs. 9.5%). CONCLUSION: In M-LIF, there were no significant differences in bone fusion score between WT- and BP-treated patients. In contrast, BC status immediately postoperatively had a major impact on 6-month bone fusion. LEVEL OF EVIDENCE: 1.
引用
- Oba H, Takahashi J, Yokomichi H, et al. Weekly Teriparatide Versus Bisphosphonate for Bone Union During 6 Months After Multi-Level Lumbar Interbody Fusion for Osteoporotic Patients: A Multicenter, Prospective, Randomized Study. Spine (Phila Pa 1976). 2020. PMID: 32049937. doi:10.1097/BRS.0000000000003426
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。